Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Craig Chepke

Psychiatry Huntersville, NC Medical Doctor

NPI 1831363712 CMS profile 501089

10225 Hickorywood Hill Ave Ste B, Huntersville, NC 28078

Open in the dashboard

General payments

$4,070,150

4,506 records reported · program years 2019–2025

Research payments

$16,000

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,702 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Craig Chepke of Huntersville, NC is reported in the CMS Open Payments database as having received $4,070,150 across 4,506 general payments and $16,000 in research payments paid to them. Separately, studies naming them as principal investigator received $23,702 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $784,645 597
2024 General $832,156 724
2023 General $809,698 711
2022 General $659,699 616
2021 General $416,967 606
2020 General $275,347 547
2020 Research $7,000 2
2019 General $291,638 705
2019 Research $9,000 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Chepke
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Craig Chepke were reported at $784,645. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Craig Chepke Psychiatry median Middle half National median
2019 $291,638 $184 $59–$605 $163
2020 $275,347 $119 $36–$372 $114
2021 $416,967 $143 $43–$576 $132
2022 $659,699 $153 $50–$590 $149
2023 $809,698 $170 $56–$651 $160
2024 $832,156 $179 $57–$673 $164
2025 $784,645 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $636,592 550 payments
  2. AbbVie, Inc. $495,249 459 payments
  3. Neurocrine Biosciences, Inc. $491,198 591 payments
  4. Axsome Therapeutics, Inc. $452,060 352 payments
  5. Otsuka America Pharmaceutical, Inc. $390,470 469 payments
  6. ITI, Inc. $376,559 353 payments
  7. E.R. Squibb & Sons, L.L.C. $196,763 168 payments
  8. Janssen Pharmaceuticals, Inc $179,184 245 payments
  9. Eisai Inc. $122,262 173 payments
  10. ACADIA Pharmaceuticals Inc $113,516 145 payments
  11. Other $616,299 1,001 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,308,386 952 payments
  2. Consulting Fee $1,031,590 322 payments
  3. Travel and Lodging $439,033 1,242 payments
  4. Honoraria $212,207 38 payments
  5. Food and Beverage $74,192 1,913 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,875 2 payments
  7. Education $1,868 37 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $373,074 360 payments
  2. INGREZZA $362,892 336 payments
  3. AUSTEDO $357,903 343 payments
  4. Auvelity $333,683 289 payments
  5. CAPLYTA $271,486 263 payments
  6. REXULTI $217,969 286 payments
  7. VRAYLAR Neuroscience $189,525 238 payments
  8. SPRAVATO $187,624 253 payments
  9. Dayvigo $122,193 172 payments
  10. Austedo XR $118,887 107 payments
  11. Other $1,617,033 2,200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $16,000 6 payments

Records

4,512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record